Group D PAH-CHD is a problematic increasingly recognized group of
patients, in which pulmonary hypertension continues to progress despite
the correction of a significant cardiac lesion with pulmonary overflow.
Early and non-invasive testing that can predict this subset of patients,
prior to correction of their underlying cardiac lesion, is still
non-established in practice and under-investigated in literature. Serum
markers and angiogenic molecules denoting apoptosis resistance, can be
game changer to the standard practice in this context. We hope that this
letter can encourage researchers concerned with PAH-CHD to start
investigating the diagnostic accuracy and cut-off values of these
biomarkers.